Overview

Study of Nivolumab and Ipilimumab Plus Chemotherapy as a Treatment for Patients With Stage IV Lung Cancer With Brain Metastases

Status:
Not yet recruiting

Trial end date:
2026-12-15

Target enrollment:

Participant gender:

Summary

This is an open-label, non-randomised, phase II, multicenter clinical trial. 71 stage IV or recurrent, non-small cell lung cancer patients with synchronous brain metastases will be enrolled in this trial to evaluate the efficacy of Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Fundación GECP

Treatments:

Carboplatin
Cisplatin
Ipilimumab
Nivolumab
Paclitaxel
Pemetrexed